Johnson & Johnson $JNJ Shares Bought by Sumitomo Life Insurance Co.

Sumitomo Life Insurance Co. boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 166.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 67,495 shares of the company’s stock after buying an additional 42,185 shares during the period. Sumitomo Life Insurance Co.’s holdings in Johnson & Johnson were worth $17,869,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of JNJ. TIAA CREF Individual & Institutional Services LLC lifted its holdings in Johnson & Johnson by 0.5% in the 3rd quarter. TIAA CREF Individual & Institutional Services LLC now owns 214,733 shares of the company’s stock valued at $56,849,000 after purchasing an additional 1,137 shares in the last quarter. FCA Corp TX lifted its stake in shares of Johnson & Johnson by 1.4% in the third quarter. FCA Corp TX now owns 19,687 shares of the company’s stock worth $5,212,000 after buying an additional 276 shares in the last quarter. Whittier Trust Co. boosted its position in Johnson & Johnson by 3.0% during the third quarter. Whittier Trust Co. now owns 191,756 shares of the company’s stock worth $50,133,000 after acquiring an additional 5,606 shares during the last quarter. TIAA Trust National Association boosted its position in Johnson & Johnson by 3.2% during the third quarter. TIAA Trust National Association now owns 14,108 shares of the company’s stock worth $3,735,000 after acquiring an additional 432 shares during the last quarter. Finally, Saranac Partners Ltd grew its stake in Johnson & Johnson by 82.5% during the 3rd quarter. Saranac Partners Ltd now owns 2,942 shares of the company’s stock valued at $804,000 after acquiring an additional 1,330 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Latest Johnson & Johnson News

These are some of the JNJ news items that stood out recently:

  • Positive Sentiment: J&J announced the first U.S. commercial installation of its OTTAVA surgical robot at a Houston hospital, an early step in bringing the platform to market and expanding its surgical-technology business. Article
  • Neutral Sentiment: JPMorgan raised its JNJ price target to $300 from $285 but kept a “neutral” rating, signaling a higher valuation estimate without a change in its overall recommendation. Analyst rating
  • Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and increased damages, reinforcing ongoing litigation exposure for J&J. Article

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. Weiss Ratings cut shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Leerink Partners dropped their price target on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. Citigroup lifted their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Finally, Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $276.54.

Get Our Latest Report on Johnson & Johnson

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.3%

NYSE JNJ opened at $270.54 on Friday. The stock has a market capitalization of $651.27 billion, a PE ratio of 40.99, a price-to-earnings-growth ratio of 2.79 and a beta of 0.22. The firm has a 50 day moving average of $267.53 and a two-hundred day moving average of $250.98. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $199.90 and a 52 week high of $290.25.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter last year, the company earned $2.80 earnings per share. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.